Spotlight on talimogene laherparepvec for the treatment of melanoma lesions in the skin and lymph nodes
Marlana Orloff Department of Medical Oncology, Thomas Jefferson University, Philadelphia, PA, USA Abstract: On October 27, 2015, talimogene laherparepvec (T-VEC), a first in class intralesional oncolytic virotherapy, was granted the US Food and Drug Administration approval for the treatment of melan...
Main Author: | Orloff M |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2016-10-01
|
Series: | Oncolytic Virotherapy |
Subjects: | |
Online Access: | https://www.dovepress.com/spotlight-on-talimogene-laherparepvec-for-the-treatment-of-melanoma-le-peer-reviewed-article-OV |
Similar Items
-
Talimogene Laherparepvec (T-VEC): An Intralesional Cancer Immunotherapy for Advanced Melanoma
by: Pier Francesco Ferrucci, et al.
Published: (2021-03-01) -
Talimogene Laherparepvec in Advanced Mucosal Melanoma of the Urethra Upon Primary Resistance on Immune Checkpoint Inhibition: A Case Report
by: Anne Fröhlich, et al.
Published: (2020-05-01) -
Talimogene laherparepvec for regionally advanced Merkel cell carcinoma: A report of 2 cases
by: Jonathan T. Blackmon, et al.
Published: (2017-05-01) -
Complete intracranial response to talimogene laherparepvec (T-Vec), pembrolizumab and whole brain radiotherapy in a patient with melanoma brain metastases refractory to dual checkpoint-inhibition
by: Zoë Blake, et al.
Published: (2018-04-01) -
Tumoral Melanosis and Separate Granulomatous Inflammation due to Talimogene Laherparepvec
by: Lee, B.A, et al.
Published: (2022)